Jefferies analysts have released exclusive market talks on the Health Care sector, covering Bayer and its challenges on multiple fronts. The halt of a late-stage clinical trial of experimental cardiovascular drug asundexian pushes financial risk to the edge, while share-price falls increase sensitivity to rising provisions and potential trial losses in a legal battle over its Roundup weedkiller. This suggests that Bayer might need to sell assets and scrap dividends to buy time, but this may not be enough for large-scale investments needed in its pharma business, according to Jefferies. As a result, Jefferies has cut its recommendation on the stock from buy to hold. Following Monday’s heavy losses, shares trade 0.3% higher.